Background: HIV-1 capsid (CA) is a viral protein essential for early and late events of the replication cycle and so far CA has been an untapped target, thus providing excellent opportunities for the discovery of new antiretrovirals that act by novel mechanisms of action. Methodology: We screened a library for compounds that interfere with multimerization of HIV-1 CA and identified a small molecule, 18E8, with antiretroviral activity of 18E8 in single- and multiple-round infection assays. To identify the antiviral target of 18E8 we selected resistance viral variants in in vitro serial passage experiments. To determine whether 18E8 affects the late step of the viral replication cycle, we conducted virus production assays, western blot analysis of viral supernatants and electron microscopy. To further gain insight into the mode of action of 18E8 and to determine the affected early step of the viral replication cycle, we performed synchronized time-of-drug-addition experiments that determine how long the addition of 18E8 could be postponed before losing its antiviral activity. To evaluate the effect of 18E8 on levels of different DNA forms, we used qPCR to detect late reverse transcriptase (RT) products, 2-LTR circles and integrated viral DNA. Results: 18E8 showed broad antiretroviral activity against drug resistant and non-clade B viruses, but not against an HIV-1 core pseudotyped with VSV-G envelop. Experiments for the selection of drug resistance revealed that an A105T CA mutation confers resistance to18E8, suggesting that it exerts its antiretroviral activity by binding to HIV-1 CA. 18E8 did not affect proper assembly of fully processed CA in nascent viral particle. By comparing its relative position in the time scale to that of drugs that target RT and integrase steps we demonstrated that 18E8 targets an early step in the HIV replication cycle, after reverse transcription. Consistent with these results, cell-cell fusion and primer extension by RT assays showed that 18E8 did not affect the viral entry or RT steps. Surprisingly, although 18E8 targeted CA, it decreased the amount of integrated viral DNA. 18E8-resistant virus carrying A105T in CA restored integration efficiency. It has been reported that antiviral host factor CPSF6 interacts with CA and restricts HIV-1 infection by preventing nuclear entry and integration of the viral dsDNA. HIV-1N74D, which is unable to bind CPSF6, maintains 50% infectivity in TNPO3-deficienct cells, and this infectivity is hypersusceptible to 18E8. Docking simulation suggests that 18E8 binds at the CPSF6 binding site and may affect interactions between the N-terminal domains of two CA monomers. Conclusions: Our data suggest that 18E8 acts during nuclear import and affects integration by interacting with CA.